MAI Capital Management’s 2seventy bio TSVT Stock Holding History

MAI Capital Management’s Portfolio TSVT Stock Details TSVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-100	Closed	-$294	–	3580
2024 Q4	$294	Buy	+100	New	+$410	﹤0.01%	3347

Other funds holding TSVT

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BCM

Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

MAI Capital Management's TSVT Position: Q1 2025 in Review

MAI Capital Management sold out of 2seventy bio (TSVT) in Q1 2025, closing a stake of 100 shares — an estimated $294 sold.

MAI Capital Management first reported a position in TSVT in Q4 2024 and held it in 1 quarter. The position peaked at $294 in Q4 2024. 139 funds tracked by Wall St. Rank hold TSVT as of Q1 2025.

MAI Capital Management reported no remaining 2seventy bio position as of Q1 2025 after selling out during the quarter.
MAI Capital Management sold 100 2seventy bio shares in Q1 2025, an estimated $294.
MAI Capital Management first reported a position in 2seventy bio in Q4 2024 and held it in 1 quarter.
MAI Capital Management's 2seventy bio position peaked at $294 in Q4 2024.
139 funds tracked by Wall St. Rank held 2seventy bio as of Q1 2025.

Based on MAI Capital Management's 13F filing for Q1 2025, filed 15 May 2025.